Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement

Published on Sep 3, 2020in Cell discovery6.255
· DOI :10.1038/S41421-020-00199-1
Jinkai Zang3
Estimated H-index: 3
(CAS: Chinese Academy of Sciences),
Chenjian Gu10
Estimated H-index: 10
(Fudan University)
+ 12 AuthorsZhong Huang29
Estimated H-index: 29
(CAS: Chinese Academy of Sciences)
Sources
Abstract
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020). CAS Article Google Scholar Amanat, F. & Krammer, F. SARS-CoV-2 vaccines: status report. Immunity 52, 583–589 (2020). CAS Article Google Scholar Chen, W. H., Strych, U., Hotez, P. J. & Bottazzi, M. E. The SARS-CoV-2 vaccine pipeline: an overview. Curr. Trop. Med. Rep. 7, 61–64 (2020). Article Google Scholar Hotez, P. J., Corry, D. B. & Bottazzi, M. E. COVID-19 vaccine design: the Janus face of immune enhancement. Nat. Rev. Immunol. 20, 347–348 (2020). CAS Article Google Scholar Huisman, W., Martina, B. E. E., Rimmelzwaan, G. F., Gruters, R. A. & Osterhaus, A. D. M. E. Vaccine-induced enhancement of viral infections. Vaccine 27, 505–512 (2009). CAS Article Google Scholar Zhou, Y. S., Jiang, S. B. & Du, L. Y. Prospects for a MERS-CoV spike vaccine. Expert Rev. Vaccines 17, 677–686 (2018). CAS Article Google Scholar Jiang, S. B., Lu, L., Liu, Q., Xu, W. & Du, L. Y. Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Emerg. Microbes Infect. 1, 1–8, e13 (2012) . Article Google Scholar Wang, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 11, 2251 (2020). CAS Article Google Scholar Block, O. K. et al. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine 28, 8085–8094 (2010). CAS Article Google Scholar Sun, J., Li, M., Wang, Y., Hao, P. & Jin, X. Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence. Vaccine 35, 6308–6320 (2017). CAS Article Google Scholar Download references We thank Dr. Xiaozhen Liang for providing A20 and K562 cell lines, Dr. Guangxun Meng for THP-1 cell line, Drs. Gary Wong and Jiaming Lan for codon-optimized S gene, Dr. Haikun Wang for assistance in flow cytometry analysis, and Xueyang Zhang, Yu Zhou, Yang Wu and Zhiping Sun for technical assistance. This study was supported by grants from the Chinese Academy of Sciences (XDB29040300) and from the Chinese Ministry of Science and Technology (2020YFC0845900). The BSL-3 lab of Fudan University was supported by Shanghai Science and Technology Committee and Project of Novel Coronavirus Research from Fudan University. These authors contributed equally: Jinkai Zang, Chenjian Gu, Bingjie Zhou, Chao Zhang, Yong Yang. CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China Jinkai Zang, Bingjie Zhou, Chao Zhang, Yong Yang, Shiqi Xu, Lulu Bai, Hong Tang, Dimitri Lavillette & Zhong Huang Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200031, China Chenjian Gu, Rong Zhang, Qiang Deng, Zhenghong Yuan & Youhua Xie BSL-3 Laboratory of Fudan University, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China Di Qu You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar Z.H., Y.X., and D.L. conceived and designed the experiments. J.Z., C.G., B.Z., C.Z., Y.Y., S.X., L.B., R.Z., Q.D., Z.Y., H.T., and D.Q. participated in multiple experiments; Z.H., Y.X., D.L., J.Z., C.G., B.Z., C.Z., and Y.Y. analyzed the data. Z.H., Y.X., D.L., and C.Z. wrote the manuscript. Z.H., Y.X., and D.L. provided the final approval of the paper. Correspondence to Dimitri Lavillette or Youhua Xie or Zhong Huang. The authors declare that they have no conflict of interest. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and Permissions Zang, J., Gu, C., Zhou, B. et al. Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement. Cell Discov 6, 61 (2020)....
Figures & Tables
Download
📖 Papers frequently viewed together
10 Authors (Jingfang Mu, ..., Xi Zhou)
40 Citations
8 Authors (Junhua Deng, ..., Kegong Tian)
7 Citations
References10
Newest
#1Chunyan Wang (UU: Utrecht University)H-Index: 9
#2Wentao Li (UU: Utrecht University)H-Index: 25
Last. Berend Jan Bosch (UU: Utrecht University)H-Index: 56
view all 10 authors...
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19. Vaccines and targeted thera...
684 CitationsSource
#1Peter J. HotezH-Index: 6
#2David B. Corry (BCM: Baylor College of Medicine)H-Index: 62
Last. Maria Elena Bottazzi (Baylor University)H-Index: 50
view all 3 authors...
Previous work on severe acute respiratory syndrome coronavirus (SARS-CoV) vaccines identified cellular immunopathology and antibody-dependent enhancement as potential safety issues. We discuss the implications of these findings for COVID-19 vaccine development and our approach to optimizing for safety and efficacy.
112 CitationsSource
#1Fatima Amanat (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 26
#2Florian Krammer (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 75
SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 170,000 individuals and caused more than 6500 deaths globally. Here we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to have an impact on the first wave of a potential pandemic. Nevertheless, important lessons can be learned for the development o...
684 CitationsSource
#1Wen-Hsiang Chen (BCM: Baylor College of Medicine)H-Index: 13
#2Ulrich Strych (BCM: Baylor College of Medicine)H-Index: 26
Last. Maria Elena Bottazzi (BCM: Baylor College of Medicine)H-Index: 50
view all 4 authors...
The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19). Previous research efforts to develop a severe acute respiratory syndrome coronavirus (SARS-CoV) vaccine in the years following the 2003 pandemic have opened the door for investigators to design vaccine concepts and approaches for the COVID-19 epidemic in China. Both SARS-CoV and SARS-CoV-2 exhibit a high degree o...
298 CitationsSource
#8Yan Zhu (CAS: Chinese Academy of Sciences)H-Index: 26
Since the SARS outbreak 18 years ago, a large number of severe acute respiratory syndrome-related coronaviruses (SARSr-CoV) have been discovered in their natural reservoir host, bats1–4. Previous studies indicated that some of those bat SARSr-CoVs have the potential to infect humans5–7. Here we report the identification and characterization of a novel coronavirus (2019-nCoV) which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China. The epidemic, which started from 12 Dece...
10.4k CitationsSource
#1Yusen ZhouH-Index: 53
#2Shibo Jiang (NYBC: New York Blood Center)H-Index: 95
Last. Lanying Du (NYBC: New York Blood Center)H-Index: 60
view all 3 authors...
ABSTRACTIntroduction: Six years have passed since Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), a newly emerging infectious virus, was first reported in 2012. Although MERS-CoV has had a consistently high mortality rate in humans, no vaccines have been approved to prevent MERS-CoV infection in humans. MERS-CoV spike (S) protein is a key target for development of MERS vaccines.Areas covered: In this review, we illustrate the structure and function of S protein as a vaccine targe...
73 CitationsSource
#1Jin Sun (CAS: Chinese Academy of Sciences)H-Index: 1
#2Min Li (CAS: Chinese Academy of Sciences)H-Index: 1
Last. Xia Jin (CAS: Chinese Academy of Sciences)H-Index: 40
view all 5 authors...
Abstract Dengue viruses (DENVs) are re-emerging pathogens transmitted by mosquitoes mainly in tropical and subtropical regions. Each year, they are estimated to infect 390 million people globally. The major challenge confronting dengue vaccine development is the need to induce balanced, long lasting tetravalent immune responses against four co-circulating virus serotypes (DENV-I, -II, -III, -IV), because primary infection by any one of which may predispose infected individuals to more severe dis...
14 CitationsSource
#1Shibo Jiang (NYBC: New York Blood Center)H-Index: 95
#2Lu Lu (Fudan University)H-Index: 41
Last. Lanying Du (NYBC: New York Blood Center)H-Index: 60
view all 5 authors...
A number of emerging and re-emerging viruses have caused epidemics or pandemics of infectious diseases leading to major devastations throughout human history. Therefore, developing effective and safe vaccines against these viruses is clearly important for the protection of at-risk populations. Our previous studies have shown that the receptor-binding domain (RBD) in the spike protein of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) is a key target for the development...
31 CitationsSource
#1Olivia K. T. Block (UR: University of Rochester)H-Index: 4
#2W. W. Shanaka I. Rodrigo (UR: University of Rochester)H-Index: 8
Last. Jacob J. Schlesinger (UR: University of Rochester)H-Index: 38
view all 6 authors...
Abstract Dengue viruses co-circulate as four serologically distinct viruses (DENV1–4) that commonly infect individuals sequentially. Current DENV candidate vaccines incorporate the entire virion envelope E protein (E) ectodomain thereby stimulating both DENV serotype-specific and cross-reactive antibodies. Because the latter may enhance naturally acquired infection, such vaccine formulations must be tetravalent. We evaluated the neutralizing and enhancing antibody response to E domain III (dIII)...
56 CitationsSource
#1Willem Huisman (EUR: Erasmus University Rotterdam)H-Index: 9
#2Byron E. E. Martina (EUR: Erasmus University Rotterdam)H-Index: 32
Last. Albert D. M. E. OsterhausH-Index: 141
view all 5 authors...
Examples of vaccine-induced enhancement of susceptibility to virus infection or of aberrant viral pathogenesis have been documented for infections by members of different virus families. Several mechanisms, many of which still are poorly understood, are at the basis of this phenomenon. Vaccine development for lentivirus infections in general, and for HIV/AIDS in particular, has been little successful. Certain experimental lentiviral vaccines even proved to be counterproductive: they rendered vac...
130 CitationsSource
Cited By33
Newest
Background null Early in the pandemic, we designed a SARS-CoV-2 peptide vaccine containing epitope regions optimized for concurrent B cell, CD4+ T cell, and CD8+ T cell stimulation. The rationale for this design was to drive both humoral and cellular immunity with high specificity while avoiding undesired effects such as antibody-dependent enhancement (ADE). null Methods null We explored the set of computationally predicted SARS-CoV-2 HLA-I and HLA-II ligands, examining protein source, concurren...
3 CitationsSource
#1Ronald R. CobbH-Index: 7
#2Joseph P. Nkolola (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 25
Last. Rita E. Chen (WashU: Washington University in St. Louis)H-Index: 24
view all 22 authors...
Human monoclonal antibody (mAb) treatments are promising for COVID-19 prevention, post-exposure prophylaxis, or therapy. However, the titer of neutralizing antibodies required for protection against SARS-CoV-2 infection remains poorly characterized. We previously described two potently neutralizing mAbs COV2-2130 and COV2-2381 targeting non-overlapping epitopes on the receptor-binding domain of SARS-CoV-2 spike protein. Here, we engineered the Fc-region of these mAbs with mutations to extend the...
Source
#1Natasha M Clark (UW: University of Wisconsin-Madison)
#2Sanath Kumar Janaka (UW: University of Wisconsin-Madison)H-Index: 6
Last. Joseph P. Connor (UW: University of Wisconsin-Madison)H-Index: 20
view all 8 authors...
The novel coronavirus SARS-CoV2, which causes COVID-19, has resulted in the death of nearly 4 million people within the last 18 months. While preventive vaccination and monoclonal antibody therapies have been rapidly developed and deployed, early in the pandemic the use of COVID-19 convalescent plasma (CCP) was a common means of passive immunization, with the theoretical risk of antibody-dependent enhancement (ADE) of viral infection remaining undetermined. Though vaccines elicit a strong and pr...
Source
#1Leandro Nuñez-Muñoz (IPN: Instituto Politécnico Nacional)
#2Gabriel Marcelino-Pérez (IPN: Instituto Politécnico Nacional)
Last. Daniela Roa-Velázquez (IPN: Instituto Politécnico Nacional)
view all 0 authors...
The Receptor-Binding Domain (RBD) of the Spike (S) protein from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has glycosylation sites which can limit the production of reliable antigens expressed in prokaryotic platforms, due to glycan-mediated evasion of the host immune response. However, protein regions without glycosylated residues capable of inducing neutralizing antibodies could be useful for antigen production in systems that do not carry the glycosylation machinery. To test...
Source
#4Chenjian Gu (Fudan University)H-Index: 10
Massive production of efficacious SARS-CoV-2 vaccines is essential for controlling the ongoing COVID-19 pandemic. We report here the preclinical development of yeast-produced receptor-binding domain (RBD)-based recombinant protein SARS-CoV-2 vaccines. We found that monomeric RBD of SARS-CoV-2 could be efficiently produced as a secreted protein from transformed Pichia pastoris (P. pastoris) yeast. Yeast-derived RBD-monomer possessed functional conformation and was able to elicit protective level ...
Source
#1Kun Xu (CAS: Chinese Academy of Sciences)H-Index: 2
#2An Yaling (CAS: Chinese Academy of Sciences)H-Index: 2
Last. Ping Gao (CAS: Chinese Academy of Sciences)H-Index: 4
view all 23 authors...
AbstractA safe and effective vaccine is urgently needed to control the unprecedented COVID-19 pandemic. Four adenovirus vectored vaccines expressing spike (S) protein have been approved for use. Here, we generated several recombinant chimpanzee adenovirus (AdC7) vaccines expressing S, receptor-binding domain (RBD) or tandem-repeat dimeric RBD (RBD-tr2). We found vaccination via either intramuscular or intranasal route was highly immunogenic in mice to elicit both humoral and cellular immune resp...
Source
#1Yong Yang (CAS: Chinese Academy of Sciences)H-Index: 45
#2Jinkai Zang (CAS: Chinese Academy of Sciences)H-Index: 3
Last. Zhong Huang (CAS: Chinese Academy of Sciences)H-Index: 29
view all 9 authors...
The ongoing coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the currently approved SARS-CoV-2 vaccines use the prototype strain-derived spike (S) protein or its receptor-binding domain (RBD) as the vaccine antigen. The emergence of several novel SARS-CoV-2 variants has raised concerns about potential immune escape. In this study, we performed an immunogenicity comparison of prototype strain-derived RBD, S1, and S ect...
Source
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback for global economy and health. SARS-CoV-2 has an exceptionally high level of transmissibility and extremely broad tissue tropism. However, the underlying molecular mechanism responsible for sustaining this degree of virulence remains largely unexplored. In this article, we review the current knowledge and crucial information...
3 CitationsSource
Eukaryotische mRNAs zahlen zu den neuartigen Modalitaten fur Proteinersatztherapien und Schutzimpfungen null Die 5′‐Kappe ist fur die mRNA‐Translation und die Immunantwort von Bedeutung und kann naturgemas durch S‐Adenosyl‐l‐Methionin (AdoMet)‐abhangige Methyltransferasen (MTasen) an verschiedenen Positionen methyliert werden null Wir berichten vom Cosubstrat‐Spektrum der MTase CAPAM, die fur die Methylierung der N6‐Position von Adenosin‐Start‐Nukleotiden verantwortlich ist und verwenden dazu sy...
Source
#1Huibin Lv (Li Ka Shing Faculty of Medicine, University of Hong Kong)H-Index: 9
#2Owen Tak Yin Tsang (Hospital Authority)H-Index: 1
Last. Chris Ka Pun Mok (Li Ka Shing Faculty of Medicine, University of Hong Kong)H-Index: 25
view all 16 authors...
The increasing numbers of infected cases of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses serious threats to public health and the global economy. Most SARS-CoV-2 neutralizing antibodies target the receptor binding domain (RBD) and some the N-terminal domain (NTD) of the spike protein, which is the major antigen of SARS-CoV-2. While the antibody response to RBD has been extensively characterized, the antigenicity and immunogenici...
Source